Kidney Disease: Improving Global Outcomes (KDIGO)

Tables, figures, and algorithms
TABLES
S8	Table 1.	Prevalence of HCV infection in hemodialysis patients from various countries
S16	Table 2.	Summary Table of baseline characteristics of hemodialysis patients tested for HCV (EIA vs. NAT)
S17	Table 3.	Summary Table of testing for HCV in hemodialysis patients (EIA vs. NAT)
S19	Table 4.	Evidence Profile for diagnostic testing for HCV in hemodialysis patients
S26	Table 5.	Recommended treatment of HCV infection in patients with CKD and their associated adverse events
S27	Table 6.	Ribavirin dosing based on creatinine clearance and targeted steady-state concentration of ribavirin
S31	Table 7.	Monotherapy with conventional interferon in dialysis patients
S32	Table 8.	Summary Table of baseline characteristics of hemodialysis patients with chronic HCV infection receiving IFN-based regimens
S33	Table 9A.	Summary Table of IFN-based regimens in hemodialysis patients with chronic HCV infection: main outcomes
S36	Table 9B.	Summary Table of IFN-based regimens in hemodialysis patients with chronic HCV infection: other outcomes described
S37	Table 10.	Evidence Profile of treatment with interferon-based regimens in hemodialysis patients with chronic HCV infection
S38	Table 11.	Summary Table of baseline characteristics of kidney transplant recipients with chronic HCV infection receiving therapy
S39	Table 12.	Summary Table of treatment in kidney transplant recipients with chronic HCV infection
S40	Table 13.	Summary Table of adverse events leading to discontinuation of treatment in kidney transplant recipients with chronic HCV infection
S41	Table 14.	Evidence Profile for treatment regimens in kidney transplant recipients with chronic HCV infection
S43	Table 15.	Summary Table of pegylated-interferon monotherapy in hemodialysis patients with chronic HCV infection
S44	Table 16.	Summary Table of pegylated interferon plus ribavirin in hemodialysis patients with chronic HCV infection
S45	Table 17.	Evidence Profile for treatment with pegylated-interferon monotherapy or pegylated interferon plus ribavirin in hemodialysis patients with chronic HCV infection
S47	Table 18.	Hygienic precautions for hemodialysis (general)
S48	Table 19.	Hygienic precautions for hemodialysis (dialysis machines)
S51	Table 20.	Summary Table of virologic investigations of HCV outbreaks in hemodialysis units
S52	Table 21.	Summary Table of epidemiologic investigations of HCV outbreaks in hemodialysis units
S66	Table 22.	Summary Table of patient mortality in HCV-positive kidney transplant recipients vs. wait-listed HCV-positive hemodialysis patients
S67	Table 23.	Summary Table of adjusted mortality and graft loss in HCV-positive vs. HCV-negative kidney transplant recipients
S68	Table 24.	Summary Table of outcomes following kidney transplantation using HCV-positive donors
S73	Table 25.	Summary Table of baseline characteristics of patients treated for HCV-associated glomerular disease
S74	Table 26.	Summary Table of effect of treatment of HCV-associated glomerular disease
S76	Table 27.	Summary Table of adverse events of treatment in HCV-associated glomerular disease
S77	Table 28.	Evidence Profile for effect of treatment of HCV-associated glomerular disease
S79	Table 29.	Histologic scoring systems of liver fibrosis
S81	Table 30.	Systematic review topics and screening criteria
S82	Table 31.	Literature search yield of primary articles for systematic review topics
S83	Table 32.	GRADE system for grading quality of evidence
S84	Table 33.	Balance of benefit and harm
S84	Table 34.	Levels of strength of recommendations

FIGURES
S13	Figure 1.	Summary receiver operating characteristic curve: EIA vs. NAT
S13	Figure 2.	Probability of HCV infection based on population prevalence and EIA test accuracy

ALGORITHMS
S10	Algorithm 1.	CKD Stage 5 hemodialysis diagnostic algorithm
S53	Algorithm 2.	Pretransplant evaluation for HCV infection
S54	Algorithm 3.	Management of the wait-listed pretransplant candidate

Mission Statement: